3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Glioma
5
Glioblastoma
2
Brain Neoplasms
2
Stomach Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms
1
Multiple Myeloma
1
Mesothelioma
1
Meningeal Carcinomatosis
1
Melanoma
1
Lymphoma, Follicular
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Myeloid
1
Gliosarcoma
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Burkitt Lymphoma
1
Breast Neoplasms
1
Astrocytoma
1
Interventions
Temozolomide
128
Radiotherapy
85
Bevacizumab
43
Radiation
30
Carmustine
29
Irinotecan
22
Erlotinib Hydrochloride
22
Magnetic Resonance Spectroscopy
21
Chemotherapy, Adjuvant
20
Surgical Procedures, Operative
15
O(6)-benzylguanine
15
Carboplatin
14
Radiotherapy, Intensity-Modulated
13
Radiotherapy, Conformal
13
sargramostim
12
Sirolimus
9
Imatinib Mesylate
9
Filgrastim
9
temsirolimus
8
Thalidomide
8
Sorafenib
8
Radiosurgery
8
Drug Therapy
8
pembrolizumab
7
motexafin gadolinium
7
aldesleukin
7
Vorinostat
7
Procarbazine
7
Gene Expression Profiling
7
Gefitinib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gliosarcoma
×
Immunotherapy, Adoptive
×
CNS
×
Clear all
NCT02664363
2023-02-17
ExCeL
Duke University
Phase 1
Terminated
3 enrolled
8 charts